Importance: CIS to MS conversion rates vary depending on population cohorts, initial 30 manifestations, and durations of follow-up. 31 Objective: To investigate conversion rate of patients from CIS to MS and the prognostic 32 significance of demographic and clinical variables in Taiwanese population. 33 Design: Nationwide, prospective, multi-centric, observational study from November 2008 to 34 November 2014 with 4 years follow-up. 35 Setting: Multi-centre setting at 5 institutions in Taiwan. 36 Participants: 152 patients having single clinical event potentially suggestive of MS in last 2 37 years were enrolled as consecutive sample. 33 patients were lost to follow-up and 16 38 patients did not complete the study.103 patients completed the study. 39 Intervention(s) (for clinical trials) or Exposure(s) (for observational studies): Natural 40 progression from first episode of CIS to MS or NMO was observed. 41 Main Outcome(s) and Measure(s): Variables analysed were 'proportion of patients 42 converting to MS or NMO after first episode of CIS', 'duration between first episode of 43 neurological event and diagnosis of MS', 'status of anti-AQP4 IgG' and 'length of longest 44 contiguous spinal cord lesion in MS patients'. Association between baseline characteristics 45 and progression to MS from CIS was analyzed using multiple logistic regression. Multivariate 46 time dependent effect of baseline characteristics on progression to MS was plotted. 47 53 amongst them, 80% were NMO patients as diagnosed by modern criteria. 54 Conclusions and Relevance: 'Below normal BMI' and 'number of demyelinating lesions (≥4)' 55 are significant predictors of conversion from CIS to MS. A low conversion rate to MS in 56 Taiwanese CIS patients and majority of them having a benign course and minimal disability 57 suggest the roles of geographic, genetic and ethnic factors. 58 Trial Registration: Non-trial observational study. 59 60 61
Results: 14.5% patients with CIS converted to MS after 1.1 ± 1.0 years with greater 48 predisposition (18.8%) in those having syndromes referable to the cerebral hemispheres. 49 Conversion rate from ON to MS was 9.7%. 90.9% patients had benign disease course. 46.7% CIS is the first clinical demyelinating event lasting ≥24 hours, prodromal to MS. It is also a stage 63 at which intervention could be effective in reducing chances of conversion to MS. Early risk 64 stratification in CIS helps to counsel the patients about prognosis and to expedite treatment 65 initiation with the goal of reducing future morbidity [1, 2] . Clinical phenotype of CIS includes 66 spinal cord syndrome (50%), optic neuritis (25%), brain stem and/or cerebellar syndrome 67 (15%), or occasionally cerebral hemispheric dysfunction [3, 4] . 68 Neuromyelitis optica (NMO) and acute demyelinating encephalomyelitis are the important 69 differential diagnosis of CIS [4] . Many patients with NMO have detectable serum IgG 70 antibodies against the water channel aquaporin-4 (AQP4-immunoglobulin G [IgG]) which are 71 very specific for clinically diagnosed NMO. Currently, routine testing for AQP4-IgG antibodies 72 is considered in high-risk individuals due to similar initial disease course in NMO and MS [5] . 73 MS is chiefly diagnosed by clinical acumen supported by investigations, including T2-weighted 74 magnetic resonance imaging (MRI), CSF evaluation, and visual evoked potential [5] .
Longitudinally-extensive spinal cord lesions are uncommon and are suggestive of NMO [4] . 76 MRI remains the most important surrogate marker for predicting the risk of a second event 77 in CIS patients (i.e conversion to MS) but the clinical outcome remains unpredictable due to 78 the high variability of this disease among individuals. Thus, a need remains for auxiliary 79 markers that could provide additional information about the disease course. 80 Various prospective, longitudinal cohort studies in CIS patients have reported the rates of 81 conversion to MS. The conversion rate from CIS to MS is reported to lie between 30%-82% 82 by different global studies [4, 6, 7, 8, 9] . The variability in conversion rates is likely attributable 83 to the cohort studied, geographic area, ethnic group, initial manifestation, and the duration 84 of follow-up. Moreover, factors like difference in patient selection method, diagnostic criteria, 85 and study design also cause variability. 86 Numerous factors influence the conversion to MS after the first episode of CIS. Of the 87 epidemiological risk factors, female gender and young age group are shown to be predictive 88 of MS after a CIS [6-11,22]. Long term studies have shown that number and activity of MRI 89 lesions and spinal cord abnormalities at the time of presentation are the strongest predictor 90 of conversion to MS [2, 12] . As regards the location, Barkhof reported 9 year cumulative incidence rate of MS in patients with ON to be 1.02% with a 98 predominance in females and younger patients. 99 None of the studies has prospectively analysed the conversion of CIS to MS in Taiwanese   100 population. The precise likelihood of further neurological events and conversion to MS is 101 essential both for patients and neurologists pertaining to timely initiation of disease 102 modifying therapies. 103 The current study was planned with the primary objective to evaluate the conversion rate potentially suggestive of MS within the last 2 years were enrolled at 5 institutions in Taiwan. 113 The study was approved by the institutional review board and ethics committee of each 114 institute and performed in accordance with the principles of the Declaration of Helsinki. 115 Written informed consent was obtained from all patients. 116 The study participants were encouraged to follow up at 12 -16 weeks in case of no event, 117 and in case of a relapse until diagnosis of MS or other disease. A telephonic interview was 118 conducted at quarterly intervals. 33 patients were lost to follow-up and 16 patients did not 119 complete the study due to other reasons. Subsequently, 103 patients completed the study. 120 The study participants had a minimum life expectancy of ≥12 weeks. (Table 3) 207 Anti-AQP4 IgG antibody status 208 Only one patient (4.5%) of all those who developed MS was with positive anti-AQP4 antibody 209 and this patient was tested positive during the relapse/symptomatic visit. As regards the 210 patients who developed NMO, 4 of 5 (80.0%) were positive for anti-AQP4 antibody.
A multivariate analysis was conducted incorporating time-dependent effect of demographic 212 and disease characteristics, clinical and radiological data available at baseline. In the 213 multivariate analysis (Fig 2) , our study cohort revealed that 'age', 'gender' and 'EDSS' had 214 non-significant association with MS conversion rate but a trend was noted. 'BMI' and 'number 215 of lesions' had significant association with probability of MS conversion. In Japan, a statistical survey of ON revealed that rate of conversion of ON to MS was 8.3% Among the patients who converted to MS, a female preponderance was seen in the ratio of 250 3:1. This finding is consistent with the well described gender predilection of MS [1, 4, 6, 7, 20] . 251 The mean age at the onset of neurological symptoms (38.6 years) in our study is similar to the 252 mean age reported by the ONTT and other major trials [7, 8, 12, 17, 18, 20] . However, contrary to other studies, we did not find any association between mean age at onset and gender with 254 the risk to MS conversion [7, 22] . 255 Our study reported that half of the patients developed MS within six months of first CIS and The duration to convert to MS from ON is generally associated with the number and location 260 of demyelinating lesions of the brain and spinal cord [6, 22] . In this study, there was a clear 261 distinction in the conversion rates between patients with and without evidence of prior 262 demyelination on brain MRI. In keeping with several previous studies, we confirmed the fact 263 that abnormal baseline brain MRI is a strong predictor for the development of MS in idiopathic 264 ON patients [7, 8, 12] . 265 The multiple sclerosis group in our study exhibited a narrow spectrum of extent of disability. Our study revealed significant association between the baseline BMI and conversion to MS. It 286 showed that being underweight is a significant risk factor for conversion from CIS to MS. 287 The analysis confirms that MRI at baseline is a robust factor predictive of conversion to introduction of highly effective disease-modifying treatments for MS, there is a need for risk 303 assessment to aptly select therapies for these patients due to the associated serious adverse 304 effects. 305 A key strength of our study was inclusion of patients from majority of medical centres in the 306 country. However, the study had some limitations, including a relatively small sample size. 307 We could not assess the vitamin D levels in this study. Also, we could not determine the effect 
